Tisotumab Vedotin as Second- or Third-Line Therapy for Recurrent Cervical Cancer

Recurrent cervical cancer has a poor prognosis. The median overall survival was nearly 1 year with tisotumab vedotin, an antibody–drug conjugate, as compared with 9.5 months with chemotherapy.

​   The New England Journal of Medicine: Search Results in Hematology/Oncology